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38 months (range: 2-95), 4 patients (9.1%) had a local relapse 
(LR) after a median time of 10 months (range: 1-26). All 
relapses occurred in T2 tumors, with 3 out of 4 presenting 
with an initial tumor size > 2.5 cm. No nodal or metastatic 
progression were observed. The actuarial 4-year LR free-
survival and colostomy free-survival were 88.7%. Overall, 5 
cases of acute grade 3 skin toxicity (4 perianal and 1 inguinal) 
and 4 cases of acute grade 3 diarrhoea were observed. No 
late grade ≥ 3 toxicity was reported. 
Conclusions: In early stage node negative anal cancers (T1-2 
measuring ≤3cm, with ≤ 50% anal circumference 
involvement), highly conformal RT techniques provide 
excellent LRC rates with an acceptable toxicity profile, at 
least comparable to those published in the literature, 
especially using a brachytherapy boost. PII to 36 Gy delivered 
with modern EBRT techniques may significantly reduce the 
risk of inguinal relapse without increasing radiation-induced 
side effects.  
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Purpose/Objective: This retrospective study evaluates the 
utility of a 3-Tesla (3T) MRI in detecting a local recurrence or 
nodal involvement in post-prostatectomy prostate cancer 
patients receiving adjuvant or salvage intensity modulated 
radiation therapy (IMRT). 
Materials and Methods: From 1/1/2006 to 5/1/2012, 90 
patients status post prostatectomy had a 3T MRI prior to 
adjuvant or salvage IMRT. Patients were grouped into those 
with positive and negative findings on MRI. The following 
variables were analyzed for their usefulness in predicting 
positive findings on MRI: pre- and post-op PSA, PSA and 
testosterone at time of imaging, PSA velocity, surgical 
margins, Gleason grade, stage, physical exam findings, and 
type of surgical prostatectomy. 
Results: Significant variables predictive of a positive MRI 
included positive margins and presence of a positive digital 
rectal exam. Furthermore, the anatomical site of tumor 
recurrence on 3T MRI was significantly associated with the 
anatomical locations of positive margins. In the vast majority 
of patients with a positive 3T MRI, imaging aided in IMRT 
treatment planning. Patients with a positive MRI finding, as 
compared without MRI findings, did not show differences in 
clinical outcome at follow-up. 
Conclusions: A pre-RT 3T MRI is useful to assess recurrences 
in prostate cancer in post-prostatectomy men with rising PSA 
levels. In order to ensure cost-effectiveness of the 3T MRI, 
assessment of tumor margins and a careful physical 
examination must be performed in order to optimize the 
chance of a positive MRI finding and thus guide treatment 
planning.  
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Purpose/Objective: The role of 18F-choline positron emission 
tomography/computed tomography (Cho- PET) in diagnosis 
and staging before definitive radiotherapy in localized 
prostate cancer patients is not standardized. Aim of the 
study is to evaluate the impact of Cho- PET decision making 
strategy in patients with localized prostate cancer eligible to 
definitive radiotherapy. 
Materials and Methods: From January 2011 to August 2014, 
sixty patients with biopsy proven prostate adenocarcinoma, 
with no prior treatment on primary tumor and staged with 
Cho-PET before radiotherapy were prospectively enrolled. 
Median age was 73 years (60-81 years); Gleason score was 6 
in 32 patients (pts), 7 in 14 pts and ≥8 in 14 pts; median PSA 
value at the diagnosis was 6.79 ng/ml (2.3-143ng/ml). All 
patients were treated with Volumetric Modulated Arc 
Therapy (Varian RapidArc®, Palo Alto - CA, USA) with 
simultaneous integrated boost in 28-30 fractions (moderate 
hypofractionation) as follow: for low risk prostate PTV only, 
for intermediate risk prostate and seminal vesicles PTVs and 
for high risk prostate, seminal vesicles and pelvic lymph 
nodes. Androgen deprivation was prescribed according to 
NCCN risk classification. Cho-PET findings were used to 
define the stage according to the detection of primary tumor 
(T), pelvic lymph nodes (N) and distant metastases (M). 
Therapeutic strategy based on the Cho-PET evaluation was 
compared to the strategy that would have been proposed in 
case of PET not available and/or not strictly indicated, 
following international and national prostate cancer 
guidelines. 
Results: Cho-PET was positive in 57 cases (95%): T (prostate 
gland only) in 46 (81% of all positive cases); T in combination 
with N( pelvic nodes) in 7 (12.5%); and M(bone) in 
combination with T or N, or both, in 4 (6.5%). After the Cho-
PET patients were stratified according to NCCN risk 
classification as follows: 26 (43%) low risk, 10 (16%) 
intermediate risk and 24 (41%) high risk. Cho-PET shifted 
treatment indication in 13 cases (21%). The changes 
regarding radiation treatment volumes were as follow: 6 
intermediate risk pts (10%) shifted to high risk and 
consequently were irradiated on prostate, seminal vesicles 
and pelvic nodes PTVs; in 7 high risk pts (11%) the Cho-PET 
showed bone and/or pelvic lymph node uptake and 
consequently a simultaneous integrated boost on PET positive 
